Effects of Dexmedetomidine During IRE Procedures for Solid Tumours

Status Completed

Clinical Trial Summary

The purpose of the study is to evaluate effects of dexmedetomidine on anaesthesia during IRE procedures for solid tumours

Clinical Trial Description

Pulsed electric current can be used to produce irreversible electroporation (IRE) of cell membranes with resulting cell death. This process has been shown to ablate tumors in animal and human studies. A pulsating direct current of 20 to 50 A and 500 to 3000 V is delivered into metastatic or primary tumors in the liver, kidney, or lung via needle electrodes inserted under computed tomography (CT) or ultrasound guidance. Patients usually require general anesthesia with muscle relaxant. Currently, circa 30 procedures have been done at our institution with good or excellent results. However, several patients have had severe pain postoperatively.

Dexmedetomidine is an α2-adrenoreceptor agonist with sedative, analgesic and anxiolytic effects, and it has more selective α2-adrenergic effect than clonidine. We will evaluate perioperative dexmedetomidine 0.4 µg/kg/hr infusion effects on hemodynamics, anesthetic consumption, and recovery profiles during anesthesia for IRE of solid organs tumours. ;

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02044224
Study type	Interventional
Source	Uppsala University Hospital
Contact
Status	Completed
Phase	Phase 4
Start date	January 2014
Completion date	September 2015

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT02902484` - Study of Nintedanib and Chemotherapy for Advanced Pancreatic Cancer	Phase 1/Phase 2
Completed	`NCT04008537` - Daily Imaging, Target Identification, and Simulated Computed Tomography-Based Stereotactic Adaptive Radiotherapy Workflow in a Novel Ring Gantry Radiotherapy Device	N/A
Recruiting	`NCT04809935` - EUS-Coeliac Plexus Block Versus Radiofrequency Ablation in Pain Relief of Patients With Malignancy	Phase 4
Not yet recruiting	`NCT03659292` - Effects of Epidural Block on the Prognosis in Patients With Pancreatic Cancer Undergoing Distal Pancreatectomy	N/A
Completed	`NCT03150615` - Enteral Nutrition After Pancreaticoduodenectomy	N/A
Recruiting	`NCT02682394` - Evaluation of Pancreatic Steatosis in Patients With Cancer of Pancreas	N/A
Recruiting	`NCT05566743` - A Study Evaluating Maintenance Therapy After First Line Chemotherapy in Metastatic Cancer Pancreas	Phase 2
Not yet recruiting	`NCT04049461` - Heterotopic Ossification in Abdominal Incision and Pancreatic Cancer
Recruiting	`NCT04164602` - The Occurence of Pancreatic Cancer Studied in Association With Newly Diagnosed Diabetes in the Elderly
Active, not recruiting	`NCT04128332` - Pre-operative Stereotactic Ablative Body Radiotherapy Followed by Immediate Surgery for Pancreatic Cancer	N/A
Recruiting	`NCT03536793` - Tumour Regulatory Molecules in Early Pancreatic Cancer Detection
Recruiting	`NCT02311439` - Induction Chemotherapy, FOLFIRINOX Followed With Concurrent Capecitabine and Radiation Therapy in Inoperable Locally Advanced Cancer of the Pancreas	Phase 2/Phase 3
Completed	`NCT02296736` - The Pre-operative Pathway in Pancreatic Head Malignancy-assessment of the Diagnostic Accuracy of Staging CT Scan
Withdrawn	`NCT04123574` - A Pilot Study of BXCL701 in Patients With Pancreatic Cancer	Early Phase 1
Not yet recruiting	`NCT03278015` - Phase 2 Trial of Gemcitabine vs S-1 vs Gemcitabine Plus Nab-paclitaxel as Adjuvant Chemotherapy of Post-operative Pancreatic Cancer Patients	Phase 2
Active, not recruiting	`NCT02905578` - A Phase 2 Trial of High-dose Ascorbate for Pancreatic Cancer (PACMAN 2.1)	Phase 2
Completed	`NCT01446458` - Phase I Study of Stereotactic Body Radiation Therapy and FOLFIRINOX in the Neoadjuvant Therapy of Pancreatic Cancer	Phase 1
Recruiting	`NCT04677244` - Echo-endoscopy Biopsy Impact on the Circulating Tumor Cell Level	N/A
Recruiting	`NCT04028479` - The Registry of Oncology Outcomes Associated With Testing and Treatment
Recruiting	`NCT06148298` - Cell-Free DNA Chromatin Immunoprecipitation (ChIP) for Diagnosing Cancer